Radium 223 Dichloride (Xofigo)®

Common name: Radium 223 Dichloride
Brand name: Xofigo®
 

What is Radium 223 Dichloride?


Radium 223 Dichloride is a radiopharmaceutical that is used to treat patients with castration-resistant prostate cancer which has spread to the bones, but has not spread to other organs in the body.
 

How is Radium 223 Dichloride administered?


Radium 223 Dichloride is administered by injection.
 

What are possible side effects of this treatment?


Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are the most common side effects experienced by those who received radium 223 dichloride. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Nausea
  • Diarrhea
  • Vomiting
  • Swelling of the arms or legs
  • Low blood cell count
 

Is Radium 223 Dichloride covered in my province or territory?

Radium 223 Dichloride is covered by provincial drug programs in:
 
  • British Columbia (special authorization)
  • Manitoba
  • Ontario
  • Québec
  • Saskatchewan
 
Radium 223 Dichloride is not covered by provincial drug programs in:
 
  • Alberta
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Prince Edward Island
  • Nunavut
  • Northwest Territories
  • Yukon
Last Reviewed: April 2018








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive